Vildagliptin (Fig. 1) is an antidiabetic drug belonging to Dipeptidyl Peptidase-4 (DPP-4) inhibitors and approved to be used in monotherapy and combination therapy to control type 2 diabetes mellitus12. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.